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Abstract: The majority of genes contributing to the heritable component of blood pressure remain
unidentified, but there is substantial evidence to suggest that common polymorphisms at loci
involved in the biosynthesis of the corticosteroids aldosterone and cortisol are important. This view
is supported by data from genome-wide association studies that consistently link the CYP17A1 locus
to blood pressure. In this review article, we describe common polymorphisms at three steroidogenic
loci (CYP11B2, CYP11B1 and CYP17A1) that alter gene transcription efficiency and levels of key
steroids, including aldosterone. However, the mechanism by which this occurs remains unclear.
While the renin angiotensin system is rightly regarded as the major driver of aldosterone secretion,
there is increasing evidence that the contribution of corticotropin (ACTH) is also significant. In light
of this, we propose that the differential response of variant CYP11B2, CYP11B1 and CYP17A1 genes
to ACTH is an important determinant of blood pressure, tending to predispose individuals with an
unfavourable genotype to hypertension.
Keywords: hypertension; ACTH; aldosterone; CYP11B2; CYP11B1; CYP17A1
1. Introduction
The importance of hypertension as a risk factor for cardiovascular and cerebrovascular disease
is well established. In addition to the environmental and lifestyle factors known to influence an
individual’s blood pressure, there is also a substantial heritable component, estimated to account for
~40% of the phenotype [1]. Over the last few decades, several large-scale studies have been mounted
to identify the locations of the genetic polymorphisms underlying this effect but, so far, only 50 or
so loci have been significantly associated with blood pressure, accounting for <5% of the heritable
component. A recent study found that most of the heritability influencing systolic blood pressure
(SBP) and diastolic blood pressure (DBP) is attributable to common genetic polymorphisms, defined
as those with a minor allele frequency (MAF) greater than 0.1, located in non-coding regions that are
probably cis-regulatory [2]. Identification of these unknown polymorphisms is highly desirable, as it
will lead to greater understanding of the mechanisms underlying blood pressure homeostasis, thereby
improving the treatment and differential diagnosis of hypertension. Investigators have employed
contrasting strategies in this search, some favouring the hypothesis-free approach of the genome-wide
association study (GWAS) on the basis that this may identify genes previously unsuspected genes of
being significant mediators of blood pressure homeostasis. Others, ourselves included, have favoured
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a candidate gene approach, reasoning that many of the responsible loci are likely to be found among
those participating in the blood pressure regulatory pathways. One such pathway is the biosynthesis
of aldosterone, primarily under the regulation of the renin–angiotensin system.
Aldosterone is formed through sequential modifications to cholesterol catalysed by a series of
steroidogenic enzymes present in the adrenocortical zona glomerulosa; the adjacent zona fasciculata,
owing to a slightly different combination of enzymes, synthesises the major glucocorticoid cortisol [3].
There are several reasons to believe that the genes encoding these steroidogenic enzymes contribute to
blood pressure variability. Firstly, aldosterone is a key regulator of blood pressure, and the secretion
rates and plasma levels of aldosterone are heritable traits [4,5]. Secondly, severe disruption of this
pathway by rare monogenic disorders affecting steroidogenic enzyme function and therefore steroid
phenotype can dramatically affect blood pressure [6]. Given that these rare mutations have such severe
outcomes, much of our work has been based on the hypothesis that more common but mild functional
polymorphisms also exist at these steroidogenic loci. Such polymorphisms, influencing the expression
or function of the steroidogenic enzymes, would have more subtle effects on steroid phenotype than
their rarer, more severe counterparts but would nonetheless result in small but clinically significant
increases in average blood pressure, ultimately predisposing carriers in combination with other
heritable and environmental factors to hypertension.
In this article, we summarise our research into common functional polymorphisms, at three
steroidogenic loci that we believe contribute to the heritable component of blood pressure: CYP11B2,
CYP11B1 and CYP17A1. We then discuss the importance of corticotropin (ACTH) to the regulation of
all three genes, present evidence to suggest that this is an underappreciated factor in the long-term
regulation of aldosterone secretion, and propose that the differential response of these polymorphic
loci to ACTH may predispose their carriers to raised blood pressure and, ultimately, hypertension.
2. CYP11B2
Given its functional role, the CYP11B2 gene is an obvious blood pressure locus candidate.
It encodes aldosterone synthase (responsible for the three final stages of aldosterone biosynthesis, from
11-deoxycorticosterone onward), which is the only adrenocortical steroidogenic enzyme unique to the
production of aldosterone. The renin-angiotensin system (RAS) and raised extracellular potassium
concentration are the principal stimulators of CYP11B2 expression; ACTH is generally regarded
as having only a short-lived effect, of far less physiological significance than the other factors [3].
The potential for modified CYP11B2 gene expression to cause significant blood pressure effects is
most starkly illustrated by the rare monogenic condition, glucocorticoid-remediable aldosteronism
(GRA), where unequal crossing-over of this locus with that of the CYP11B1 gene (see below), leads to
vastly increased expression of aldosterone synthase, elevating levels of aldosterone and resulting in
severe hypertension [6]. Clearly, any CYP11B2 polymorphism with a role in population blood pressure
variation should be much more common than GRA-causing mutations, and less pronounced in its
effect. In order to support the hypothesis that CYP11B2 is an important blood pressure locus, it was
therefore necessary to demonstrate firstly that such common polymorphisms exist at the CYP11B2
locus and secondly that they have a functional effect on steroid phenotype. In the 30 years since its
sequence was first published [7], numerous common CYP11B2 polymorphisms have indeed been
identified, the most studied of which is the rs1799998 C/T single-nucleotide polymorphism (SNP), also
referred to as “-344” given its base position relative to the gene transcription start site. It is extremely
common—its minor allele frequency (MAF) is ~0.43 in Western European populations [8] and studies
have shown that its T allele associates with higher excretion rate of the major urinary aldosterone
metabolite, tetrahydroaldosterone (THaldo) [9]. However, no clear consensus has emerged on whether
this polymorphism associates with changes in blood pressure [10–13]. Meta-analysis of 42 individual
studies did show an association of rs1799998 with essential hypertension, but not with systolic or
diastolic blood pressure [10]. According to in vitro studies, the effect of this SNP on CYP11B2 gene
transcription is significant only following stimulation with angiotensin II; even then, the effect is
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small [14]. We believe this lack of clarity regarding rs1799998 effect may be due to its having no
functional impact itself, and from it being in tight but not complete linkage disequilibrium (LD) with a
functional polymorphism lying nearby. One such polymorphism, which we have studied extensively,
is rs13268025.
The rs13268025 polymorphism is a C/T SNP positioned 1651 bases upstream of the CYP11B2
transcription start site; its alleles are of almost equal frequency in our West of Scotland study
population (MAF = 0.47) and it displays a high degree of LD with rs1799998 (D’ > 0.95). Our study of
60 normotensive subjects showed that those homozygous for the C allele excreted significantly higher
quantities of THaldo in a 24 h period than the T homozygotes [15]. Reporter gene assays compared
the transcriptional activity of the CYP11B2 promoter in its alternative rs13268025 forms and were
consistent with our in vitro studies: this SNP at the 1651 position significantly affected gene activity,
with the C form being more transcriptionally active under basal conditions. This difference in activity
between the alternative alleles became even more pronounced following angiotensin II stimulation.
We have linked this change in activity to the disruption of a binding site for the transcriptional repressor
molecule apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) at the 1651 position. APEX1 has
lower affinity for the C form of rs13268025, reducing its inhibitory effect on CYP11B2 transcription [15].
(Interestingly, although knockout of APEX1 is lethal in mice, heterozygous null mice are viable and
have markedly elevated blood pressure [16].)
So, in rs13268025 we have a common polymorphism, carried by approximately half of our study
population in either homozygotic or heterozygotic form, which alters transcriptional activity of the
aldosterone synthase gene and associates with a corresponding change in steroid phenotype, while
also being physically linked to a well-researched polymorphism at the same locus (rs1799998), which
has itself been significantly associated with functional effects. This identifies CYP11B2 as a locus
harbouring at least one common polymorphism of functional effect that could influence blood pressure
and predispose carriers of the “derepressed” C allele to hypertension.
Surprisingly, the strongest association of CYP11B2 genotype with steroid phenotype to emerge
from these studies was not with aldosterone but with 11-deoxysteroids, which one would expect to
be primarily influenced by CYP11B1, the gene encoding the 11β-hydroxylase enzyme, rather than
CYP11B2 [17]. This relationship between CYP11B2 polymorphisms and indices of CYP11B1 function
is not as unlikely as it might first appear; the two genes lie side by side on human chromosome 8,
approximately 40 kilobases apart, and our studies show that their physical linkage could underlie
this observation.
3. CYP11B1
CYP11B1 encodes 11β-hydroxylase responsible for the final catalytic conversion in the
biosynthesis of cortisol. The gene is expressed within the adrenocortical zona fasciculata, and to
a lesser extent the zona reticularis, predominantly under the regulation of ACTH, acting through cyclic
AMP (cAMP) as a second messenger. The strict zonal distribution of expression within the normal
adrenal gland dictates that CYP11B1 is not coexpressed with CYP11B2, expression of which is confined
to the zona glomerulosa [6]. Nevertheless, strong association of the CYP11B2 polymorphism rs1799998
with indices of 11β-hydroxylase activity, such as levels of urinary 11-deoxycortisol metabolites, have
been observed in several studies [17–19]. This is the result of LD extending across the entire digenic
locus, causing certain CYP11B2 polymorphisms to associate with functional CYP11B1 SNPs and,
therefore, 11β-hydroxylation of steroids.
One such functional SNP at CYP11B1 is the G/T SNP rs142570922, located 1889 bases upstream of
the transcription start site. Analysis of 408 hypertensive subjects show that, in comparison to carriers of
the major G allele (where MAF = 0.49), those with the minor T allele are predisposed to a higher ratio of
tetrahydrodeoxycortisol (THS) to cortisol metabolites in their urine, reflecting lower 11β-hydroxylation
efficiency [20]. Subsequent analysis of adrenal tissue from individuals heterozygous for rs142570922
Int. J. Mol. Sci. 2017, 18, 579 4 of 11
shows that this T form of CYP11B1 is transcribed at a significantly lower rate than its G form; lower
expression is consistent with the observed inefficiency of 11β-hydroxylation [8].
Given the presence of a common functional SNP within CYP11B2 that is significantly associated
with levels of cortisol, a steroid that influences blood pressure, there is strong evidence to suggest
that CYP11B1, like CYP11B2, is a blood pressure locus. As with CYP11B2, support comes from rare
monogenic disorders of CYP11B1. Various inactivating mutations at this locus have been described
that result in deficient 11β-hydroxylation and, depending on their severity, reduced or completely
absent cortisol production. The consequent accumulation of ACTH-dependent 11-deoxycorticosterone
(DOC), which has mineralocorticoid properties, can in such instances be high enough to result in
severe hypertension. Efforts to attain normal levels of cortisol lead to elevated ACTH secretion and
hyperplasia of the adrenal cortex [21].
The observation that these two key genes of the corticosteroid pathway are each capable
independently of influencing blood pressure would be interesting enough in itself, but their physical
linkage adds an extra dimension that is likely to augment their hypertensive role. As mentioned
previously, our analysis of the digenic CYP11B1/CYP11B2 locus on chromosome 8 shows that LD
extends across both genes, such that the presence of a particular allele at a polymorphic site in CYP11B1
is a strong indicator that a particular polymorphic form exists within CYP11B2. This is the case for the
two functional SNPs we have described: the C form of rs13268025 at CYP11B2, which is associated
with a raised aldosterone excretion rate, is in significant LD with the T form of rs142570922 at CYP11B1,
which is associated with reduced 11β-hydroxylation. These two potentially hypertensive alleles tend,
therefore, to be co-inherited. Furthermore, we propose that their combined effect on blood pressure
may be synergistic.
Our proposed mechanism for this arises from three separate elements. The first two have already
been mentioned with reference to severe monogenic 11β-hydroxylase deficiency: the massive rise in
ACTH secretion and the expansion of adrenocortical volume it causes in an attempt to restore cortisol
biosynthetic capacity. The third element concerns a known but, we would argue, underappreciated
factor in aldosterone biosynthesis: its regulation by ACTH. ACTH acutely stimulates aldosterone
biosynthesis by both increasing adrenal blood flow and interacting with specific G protein-coupled
receptors in the zona glomerulosa, which influences the expression of steroidogenic genes containing
cAMP-responsive elements; these include CYP11B2 [22]. However, several studies showed that
prolonged administration of ACTH could not sustain aldosterone secretion and that it would fall
back to basal levels after approximately three to five days [23–25]. Although the mechanism for this
suppression remains unknown, such findings feed the general perception that ACTH cannot influence
aldosterone biosynthesis for anything other than short periods of time, and that its long-term effect
is inhibitory. However, we have proposed that the suppression of aldosterone biosynthesis under
chronic exposure to ACTH is a consequence of abnormally high doses, whereas chronic exposure
to only mildly increased endogenous ACTH secretion could permit the sustainable stimulation of
aldosterone secretion [3]. We examine evidence for this in greater detail below but, for now, let us
consider the consequences for individuals carrying the T form of rs142570922 at CYP11B1 if such a
prolonged and increased ACTH influence on aldosterone were to exist. As the indisputably prime
regulator of cortisol biosynthesis and of CYP11B1 expression, carriers of this polymorphism would
experience mild, relative 11β-hydroxylase inefficiency due to the slight reduction in transcriptional
efficiency it causes. Such individuals would have to prevent the small but significant drop in cortisol
biosynthesis that would result by increasing ACTH secretion slightly but chronically. Although
analogous to the increased ACTH release observed in severe 11β-hydroxylase deficiency, we argue
that this milder form would differ in two key ways. Firstly, hypertrophy of the adrenal cortex would be
a much slower and more gradual process, reflecting the relatively small rise in ACTH level. Secondly,
the magnitude of this increase would not be sufficient to trigger the suppression of aldosterone
secretion commonly observed when the adrenal cortex is chronically exposed to higher levels of ACTH.
Instead, over the lifetime of its carriers, the rs142570922 T polymorphism at CYP11B1 would induce
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very gradual hypertrophy and a mild but sustained elevation of aldosterone biosynthesis through
ACTH stimulation. As we have observed, this polymorphism cannot be considered in isolation:
it is highly likely to be co-inherited alongside the C form of rs13268025 at CYP11B2, which itself
also predisposes to slightly increased aldosterone secretion. Furthermore, as a component of the
adrenocortical hypertrophy consequent upon raised ACTH, there is likely to be zona glomerulosa
hypertrophy, further increasing its aldosterone biosynthetic capacity and/or its responsiveness to
stimulators of aldosterone secretion such as angiotensin II (or ACTH itself). In summary, due to the
interplay of these two linked polymorphisms at adjacent steroidogenic genes, we anticipate a small but
chronic rise in ACTH which, over a lifetime, significantly increases aldosterone secretion and drives
genetically predisposed carriers toward hypertension.
This mechanism was first proposed several years ago [26] and, although we have since been
able to refine and confirm certain details, certain aspects remain unproven. This is largely due to
the subtle and extremely long-term nature of the proposed effects, which are too small to measure
or detect, and to the difficulty in demonstrating that such a small increase in ACTH secretion would
stimulate aldosterone secretion without causing the inhibition of secretion many still associate with
long-term exposure. There is some further supporting evidence: in a small group of patients subjected
to low-dose dexamethasone suppression, those who were homozygous for the T form of rs142570922
at CYP11B1 had a small but significantly higher level of plasma ACTH compared to G homozygotes.
Plasma cortisol levels did not change significantly between the different genotypes, but there was an
apparent trend towards a raised cortisol:ACTH ratio in the T group [27]. This supports the existence
of an increased ACTH drive in these individuals sustaining cortisol levels, in line with our proposal.
Further investigation is ongoing to verify this hypothesis. For example, we have recent preliminary
data from 100 normotensive volunteers who were infused with corticotropin-releasing hormone;
this suggests that individuals with the genotype rs142570922 T at CYP11B1 and/or rs13268025 G
at CYP11B2 respond more vigorously in terms of ACTH and ACTH-dependent steroids (cortisol,
corticosterone and deoxycortisol) than individuals of the alternative genotypes [28].
Meanwhile, data emerging from GWAS specifically designed to identify loci of importance in
blood pressure regulation also drew attention to the corticosteroid pathway, but the locus they were
consistently highlighting was not CYP11B2 or CYP11B1, but CYP17A1 [29,30].
4. CYP17A1
Over the last decade, GWAS methodology has been applied to numerous complex traits, including
blood pressure, with the intention of discovering associations between disease and common genetic
polymorphisms. Its potential to identify loci previously unsuspected to influence certain phenotypes
was presented as a key advantage over the candidate gene approach. However, as GWAS results
emerged, there was a common perception that such studies were not delivering on their initial promise
and that a great number of relevant loci remained undetected (false negatives). Counter-arguments
hold that GWAS was never intended to identify all loci contributing to a particular trait, and that
such studies have led to new and meaningful new biological knowledge, while also confirming the
importance of key genes and pathways previously suspected of playing a role in disease [31].
Data from blood pressure GWAS conducted on European subjects by the Global BPgen and
CHARGE consortia were published in 2009 [29,30]. These, combined with further meta-analysis [32],
identified a total of 28 loci significantly associated with systolic and/or diastolic blood pressure.
CYP11B1 and CYP11B2 were not among them. However, a region on the long arm of chromosome 10 at
or near the CYP17A1 gene was consistently identified, and was associated with the greatest effect size
of all the 28 loci: ~1 mm Hg of systolic blood pressure per allele. The tag marker employed by Global
BPgen at this locus was rs11191548, which lies within a cluster of six genes, including CYP17A1; the tag
marker used by CHARGE was rs1004467 [30], found within intron 3 of CYP17A1 [29]. This association
is not limited to European populations [33–38]. The same locus has recently been associated with
birthweight, which itself inversely correlates to blood pressure in later life [39]; there is also evidence
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that control of aldosterone secretion associates with birthweight and that this effect may derive from
the hypothalamic-pituitary-adrenal (HPA) axis [40]. In light of the compelling GWAS data and the
known role of this gene in corticosteroid biosynthesis and blood pressure, we investigated it further.
The CYP17A1 gene encodes a microsomal cytochrome P450 enzyme commonly named for its
catalytic function: 17α-hydroxylase. In the adrenal zona fasciculata, this enables the enzyme to convert
pregenenolone to 17α-hydroxypregnenolone and progesterone to 17α-hydroxyprogesterone, which is
essential to the synthesis of cortisol. However, it also possesses a lyase function enabling the cleavage
of the C17,20 bond of each of these products. In the zona reticularis, this permits the production of
dehydroepiandrosterone and androstenedione (CYP17A1 is also expressed in the gonads) [6,41]. Here,
we will focus on its 17α-hydroxylase activity in the zona reticularis.
Like CYP11B1, the CYP17A1 gene is primarily regulated by ACTH; this activates signalling
cascades involving the intracellular second messenger cAMP, which promotes gene expression through
the binding of transcription factors including steroidogenic factor 1 (SF-1), GATA-binding factor 6
(GATA-6) and sterol regulatory element-binding protein 1 (SREBP-1) [42]. Loss of 17α-hydroxylase
activity due to CYP17A1 mutation can, as with 11β-hydroxylase deficiency, reduce cortisol synthesis
and lead to a surge in ACTH secretion, plus the accumulation of DOC [6]. This results in hypertension,
DOC-dependent sodium accumulation, the suppression of aldosterone secretion and hypokalaemia;
grossly raised levels of corticosterone compensate for the lack of cortisol. Sexual development is also
affected, reflecting the role of CYP17A1 in androgen production. We therefore hypothesised that,
as with CYP11B1 and CYP11B2, functional polymorphisms exist at the CYP17A1 locus, which alter
the corticosteroid phenotype and influence blood pressure. To explain the blood pressure GWAS
associations, any such polymorphism at CYP17A1 would also have to be in LD with the tag SNPs
employed by those studies and have a fairly common frequency within the general population.
Our initial screen of the entire CYP17A1 locus in a cohort of 60 normotensive volunteers identified
36 polymorphisms, of which 24 were common, with a MAF > 0.05 [43]. Of these 24, none were missense
and several were intronic, although not at splice sites. We therefore focused our attention on the 7 SNPs
that lay between the transcription start site and the limit of our sequencing, ~2 kilobases upstream,
reasoning that these might influence transcriptional regulation. Linkage analysis identified two distinct
LD blocks: while one block contains six of the SNPs, but none of the GWAS tag SNPs, the other contains
the remaining CYP17A1 SNP rs138009835 and is in significant LD with the rs1004467 SNP, shown by
the CHARGE GWAS to associate with blood pressure. Therefore, of all the polymorphisms identified
during our screen of the CYP17A1 locus, only rs138009835, a G/A SNP with a MAF of 0.11, located
1.8 kilobases upstream of the transcription start site, emerges as a SNP plausibly underlying the blood
pressure GWAS association.
Our subsequent analysis of the SNP rs138009835 in 232 hypertensive members of the British
Genetics of Hypertension (BRIGHT) cohort showed that individuals homozygous for the major G
allele had significantly increased THaldo excretion rates but no association with the excretion rates of
metabolites of cortisol, deoxycortisol or androgens [43]. Reporter gene analysis also showed this G
allele to associate with significantly higher transcriptional activity in vitro, under basal conditions and
following dibutyryl cAMP stimulation (which is used to imitate ACTH in the H295R adrenocortical
cell model that lacks ACTH receptors). In summary, the G form of rs138009835 associates with higher
CYP17A1 gene expression in vitro, increased aldosterone secretion in vivo and, through its linkage to
the A allele of the rs1004467 tag SNP, raised blood pressure.
Superficially, this appears to present a simple mechanism whereby functional changes in the
steroidogenic CYP17A1 gene might affect aldosterone phenotype, with a corresponding effect on
blood pressure. However, it is not immediately clear how such changes in CYP17A1 function translate
into altered aldosterone production, given that CYP17A1 is not expressed in the zona glomerulosa
and therefore has no direct role in aldosterone biosynthesis. One possibility is that CYP17A1 and
aldosterone share a common regulatory factor that connects the two and underlies our observed effect.
Interestingly, previous clinical studies conducted by our group show highly significant correlation of
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urinary THaldo excretion with that of cortisol metabolites [44]. Data from that same study also show
correlation of these with urinary androgen metabolite excretion, implying that aldosterone, cortisol
and androgens are under the regulation of a common factor. We propose that this common factor is
ACTH, and that it is a significant regulator of these steroids throughout life.
5. ACTH
Due to the presence of ACTH/cAMP-responsive elements at each gene promoter, CYP11B1,
CYP11B2 and CYP17A1 transcription are all regulated by ACTH [22]. While the role of ACTH in
regulating CYP11B1 and CYP17A1 (and by extension cortisol and androgen secretion) is relatively
straightforward, its control of CYP11B2 and aldosterone production in the zona glomerulosa is more
complex and not fully understood [45]. Our proposal that common polymorphisms of these three genes
have a significant influence over aldosterone levels rests, in part, on ACTH having a more significant
and enduring role in regulating its secretion than has generally been acknowledged. Evidence exists to
support this view.
Although early studies suggested that chronic ACTH might ultimately inhibit aldosterone
secretion, this is not necessarily the case. Continuous ACTH infusion does indeed cause aldosterone to
rise then fall back to baseline levels within 72 h, but ACTH administered in a pulsatile manner that
more closely models its actual secretion maintains aldosterone secretion at a raised level over this
time period [46]. Furthermore, ACTH appears to be an extremely potent regulator of aldosterone,
capable of eliciting its secretion at doses far lower than those required for cortisol or DHEA [47].
That being the case, could ACTH be a significant driver of aldosterone secretion? Correlation does
exist between ACTH and aldosterone levels; each follows a circadian rhythm, peaking in the morning
and falling throughout the day [48]. While this synchronization does suggest a causative relationship
between the two, elements of the RAAS also display diurnal variation—albeit less consistently—and
its contribution to this effect cannot be ruled out [49].
ACTH is also released following physical or psychological stress and a recent study by Markou et
al. suggests not only that ACTH release driven by such stress can promote aldosterone secretion, but
that certain individuals are highly sensitive to this stimulus. The investigators recruited 143 essentially
hypertensive subjects, carefully phenotyped to exclude any cases of primary aldosteronism. To simulate
low-grade chronic stress, this cohort was then given ultra-low doses (0.03 µg) of ACTH. This caused a
rise in plasma cortisol levels indistinguishable between the hypertensives and a normotensive control
group over the 30-min study period. However, analysis of plasma aldosterone levels revealed that the
essential hypertensives actually consisted of two distinct subgroups: approximately three-quarters
had a small but distinct rise in plasma aldosterone, again identical to that of the normotensives.
The remaining quarter, though, were termed “hyper-responders” due to their aldosterone levels
being approximately four times higher than those of the other subjects. The aldosterone:renin ratio of
hyper-responders was also significantly elevated, suggesting the stimulatory effect of ACTH in these
individuals occurs independently of the RAAS. Subjects then underwent a treadmill test, as a form of
acute physical stress. Again, the hyper-responders produced inappropriately high levels of aldosterone
when compared to the remainder of the hypertensives and the normotensive group, whose responses
were indistinguishable from one another; in contrast, the cortisol responses did not differ significantly
across hyper-responders, other hypertensives or normotensives. Consequently, the authors proposed
that the glomerulosa cells of the hyper-secretors are “primed by stress-induced ACTH secretion, which
makes them more sensitive to any increase in either ACTH or renin/angiotensin II levels” and that
this could be related to “gene mutations increasing the zona glomerulosa responsiveness to excitatory
stimuli” [50]. As John Funder concluded in his commentary on this study, “When validated, attention
should focus on ACTH and on the mechanism(s) whereby it elicits an exaggerated aldosterone response
in a substantial minority of patients otherwise classified as essential hypertensives” [51].
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6. ACTH Interaction with Polymorphic Steroidogenic Loci as a Determinant of Aldosterone
Secretion and Blood Pressure
ACTH levels directly influence cortisol and androgen levels, and vice versa. Rare monogenic
deficiencies at CYP11B1 and CYP17A1 demonstrate the impact of these loci on circulating levels of
ACTH through feedback mechanisms. However, as we have described, there is now compelling
evidence that ACTH is a more significant driver of aldosterone secretion than previously thought.
This implies the existence of a complex and dynamic situation whereby three different sets of
components each interact with and modulate the levels of one another, namely:
(1) circulating levels of ACTH;
(2) gene expression of ACTH-responsive steroidogenic loci (including CYP11B1 and CYP17A1, but
also CYP11B2);
(3) circulating levels of corticosteroids (including cortisol and androgens, but also aldosterone).
A change in any one of these would alter the states of the other two (and probably of other, as yet
unidentified) components involved in the homeostasis of this highly dynamic system.
Altered responsiveness of any of these components to one another would tend to push individuals
towards higher or lower blood pressure, adding further complexity to this system. We propose that
such changes in sensitivity result from common polymorphisms at CYP11B1, CYP17A1 and CYP11B2,
each of which are capable of significantly influencing these genes’ expression and thereby shifting the
balance of circulating steroids. Therefore, an individual’s ability to secrete aldosterone in response to a
given dose of ACTH would be significantly determined by the array of functional polymorphisms
at key steroidogenic loci. This is analogous to the ACTH sensitivity observed by Markou et al. [50].
Their proposal that polymorphisms at the KCNJ5 gene might contribute toward ‘hyper-responsiveness’
was not borne out by their sequencing of this locus. The genotyping of key SNPs at CYP11B2, CYP11B1
and CYP17A1 in such individuals would be of great interest.
We acknowledge that the observed effects of the three key polymorphisms we have described at
CYP11B1, CYP11B2 and CYP17A1 are not entirely consistent with a predisposition to hypertension.
Specifically, while we found that the form of CYP17A1 causing higher activity is apparently associated
with raised blood pressure, this runs contrary to the evidence that 17α-hydroxylation has an inverse
relationship with blood pressure [52]. However, we propose that interaction between ACTH and these
three loci is highly complex, and probably incorporates further factors in order to ultimately determine
blood pressure. Therefore, we must be cautious in extrapolating the consequences of an isolated effect
observed in vitro to the full complex system in vivo. The fact remains that genotype significantly
affects function and will have consequences that must be integrated into the developing model.
7. Conclusions
In this article we have summarised evidence that common functional polymorphisms exist
at the CYP11B1, CYP11B2 and CYP17A1 loci, and have hypothesised that each may predispose to
hypertension. Previously, we had proposed ACTH via the CYP11B1 and CYP11B2 polymorphisms
to be a key mediator in this hypertensive drive. Since then, data identifying the ACTH-regulated
CYP17A1 gene as a key blood pressure locus, the association of a common functional CYP17A1
polymorphism with aldosterone phenotype and the discovery that a sizeable proportion of essential
hypertensives secrete inappropriately high levels of aldosterone in response to ACTH has led us
to develop and refine this initial model. Our future work will focus on establishing whether these
polymorphisms contribute towards the hyper-secretion of aldosterone in response to ACTH.
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